BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics


BioXcel Therapeutics, Inc. (BTAI): $12.42

-0.42 (-3.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BTAI Stock Price Chart Interactive Chart >

Price chart for BTAI

BTAI Price/Volume Stats

Current price $12.42 52-week high $36.49
Prev. close $12.84 52-week low $8.80
Day low $12.21 Volume 385,900
Day high $13.00 Avg. volume 631,159
50-day MA $12.16 Dividend yield N/A
200-day MA $20.26 Market Cap 347.57M

BioXcel Therapeutics, Inc. (BTAI) Company Bio


BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.


BTAI Latest News Stream


Event/Time News Detail
Loading, please wait...

BTAI Latest Social Stream


Loading social stream, please wait...

View Full BTAI Social Stream

Latest BTAI News From Around the Web

Below are the latest news stories about BioXcel Therapeutics Inc that investors may wish to consider to help them evaluate BTAI as an investment opportunity.

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and w

Yahoo | February 24, 2022

BioXCel agitation with bipolar drug meets primary and secondary endpoints in phase 3

BioXCel Therapeutics (BTAI) said that a phase 3 trial of BXCL501 (sublingual dexmedetomidine) for agitation associated with bipolar disorder demonstrated statistically significant changes.

Seeking Alpha | February 22, 2022

BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar Disorders

BXCL501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo BXCL501 PDUFA Date is April 5, 2022 for acute treatment of agitation associated with schizophrenia and bipolar disorders NEW HAVEN, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in ne

Yahoo | February 22, 2022

BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate Cancer

BioXcel Therapeutics Inc (NASDAQ: BTAI ) announced results from its ongoing Phase 2 trial of BXCL701 in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype. Results will be highlighted in two poster presentations at the 2022 ASCO Genitourinary Cancers Symposium. The trial is evaluating the combination of BXCL701 with Merck & Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab). SCNC Findings: In the evaluable patient cohort (n = 15),

Benzinga | February 15, 2022

IQVIA Holdings' Q4 Beats Street View, Lifts FY22 Earnings Guidance

View more earnings on IQVSee more from BenzingaBioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate CancerHenry Schein Q4 Topline, Bottom Line Beat Street View, FY22 Outlook Exceeds Consensus© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Yahoo | February 15, 2022

Read More 'BTAI' Stories Here

BTAI Price Returns

1-mo N/A
3-mo -40.60%
6-mo -38.91%
1-year -59.45%
3-year 13.32%
5-year N/A
YTD -38.91%
2021 -56.00%
2020 216.22%
2019 278.50%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5502 seconds.